GSK

Neutral

GSK posts Q1 beat and reaffirms outlook (GSK:NYSE)

GSK reported better-than-expected financials for Q1 2026, driven by strong sales in its HIV and cancer medicine portfolios. These gains successfully c...

Seeking Alpha 1 week ago 0

Bullish

GSK Expands Share Buyback, Lifts Treasury Stock to 6.42% of Voting Rights

GSK has continued its share buyback program, repurchasing 335,000 ordinary shares on April 21, 2026, and holding them in treasury. This action increas...

TipRanks 2 weeks ago 0

Neutral

GSK Expands Share Buyback, Lifts Treasury Holding to 6.41% of Voting Rights

GSK has repurchased 330,000 ordinary shares on April 20, 2026, as part of its ongoing share buyback program, bringing its treasury holdings to 6.41% o...

TipRanks 3 weeks ago 0

Bullish

GSK Expands Treasury Stock With Latest £7m Share Buyback Tranche

GSK has continued its share buyback program, repurchasing 330,000 ordinary shares on April 17, 2026, for £7 million, adding them to treasury. This lat...

TipRanks 3 weeks ago 0

Bullish

GSK Wins China Approval For Blenrep In Previously Treated Multiple Myeloma

GSK has received approval from China's National Medical Products Administration for Blenrep (belantamab mafodotin) in combination with bortezomib and ...

DirectorsTalk Interviews 3 weeks ago 0